Literature DB >> 28760332

Evidence of surgical treatments for intractable Meniere's disease.

Tadashi Kitahara1.   

Abstract

Meniere's disease is an inner ear disease, characterized by recurrent rotatory vertigo, sensorineural hearing loss and tinnitus. There are some with frequent vertigo attacks, progressive hearing loss and persistent annoying tinnitus even through the continuous standard medical treatments. These cases are thought to account for 10%-20% of all cases of Meniere's disease. In this review article, we would like to demonstrate the evidences for surgical treatments according to the previous papers, and consider the next therapeutic strategies including surgical options according to the international guidelines.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Decompression; Endolymphatic sac surgery; Intractable Meniere’s disease; Local steroids; Shunt; Silastic sheet

Mesh:

Substances:

Year:  2017        PMID: 28760332     DOI: 10.1016/j.anl.2017.07.016

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  3 in total

Review 1.  Beyond Tympanomastoidectomy: A Review of Less Common Postoperative Temporal Bone CT Findings.

Authors:  A Panda; M L Carlson; F E Diehn; J I Lane
Journal:  AJNR Am J Neuroradiol       Date:  2020-11-12       Impact factor: 3.825

2.  Case Report: Preservation of Otolithic Function After Triple Semicircular Canal Occlusion in a Patient With Intractable Ménière Disease.

Authors:  Yuzhong Zhang; Ying Cheng; Zichen Chen; Feiyun Chen; Qing Zhang
Journal:  Front Neurol       Date:  2021-12-23       Impact factor: 4.003

3.  A Comparison of Local Endolymphatic Sac Decompression, Endolymphatic Mastoid Shunt, and Wide Endolymphatic Sac Decompression in the Treatment of Intractable Meniere's Disease: A Short-Term Follow-Up Investigation.

Authors:  Guiliang Zheng; Yupeng Liu; Jingchun He; Shuna Li; Qing Zhang; Maoli Duan; Jun Yang; Yulian Jin
Journal:  Front Neurol       Date:  2022-02-10       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.